Nuvation Bio (NUVB) Competitors

Nuvation Bio (NYSE:NUVB) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, community ranking, analyst recommendations, valuation and risk.

Do insiders and institutionals have more ownership in NUVB or RYTM?

61.7% of Nuvation Bio shares are owned by institutional investors. 5.1% of Nuvation Bio shares are owned by insiders. Comparatively, 5.6% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has better earnings & valuation, NUVB or RYTM?

Nuvation Bio has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	N/A	N/A	-$75.80M	-$2.17	-1.22
Rhythm Pharmaceuticals	$77.43M	45.49	-$184.68M	-$4.33	-13.23

Is NUVB or RYTM more profitable?

Nuvation Bio has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Nuvation Bio's return on equity of -21.89% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	N/A	-21.89%	-17.86%
Rhythm Pharmaceuticals	-230.07%	-367.36%	-77.47%

Do analysts rate NUVB or RYTM?

Nuvation Bio currently has a consensus price target of $8.20, indicating a potential upside of 209.08%. Rhythm Pharmaceuticals has a consensus price target of $68.09, indicating a potential upside of 18.82%. Given Nuvation Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Nuvation Bio is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Rhythm Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.91

Does the MarketBeat Community believe in NUVB or RYTM?

Rhythm Pharmaceuticals received 248 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 80.00% of users gave Nuvation Bio an outperform vote while only 67.12% of users gave Rhythm Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Nuvation Bio	Outperform Votes 48 80.00%	Underperform Votes 12 20.00%
Rhythm Pharmaceuticals	Outperform Votes 296 67.12%	Underperform Votes 145 32.88%

Which has more volatility & risk, NUVB or RYTM?

Nuvation Bio has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.16, meaning that its stock price is 116% more volatile than the S&P 500.

Does the media prefer NUVB or RYTM?

In the previous week, Nuvation Bio and Nuvation Bio both had 3 articles in the media. Rhythm Pharmaceuticals' average media sentiment score of 0.99 beat Nuvation Bio's score of 0.63 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nuvation Bio beats Rhythm Pharmaceuticals on 10 of the 16 factors compared between the two stocks.